Literature DB >> 20498311

Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.

Bart Hoorelbeke1, Dana Huskens, Geoffrey Férir, Katrien O François, Atsushi Takahashi, Kristel Van Laethem, Dominique Schols, Haruo Tanaka, Jan Balzarini.   

Abstract

The lectin actinohivin (AH) is a monomeric carbohydrate-binding agent (CBA) with three carbohydrate-binding sites. AH strongly interacts with gp120 derived from different X4 and R5 human immunodeficiency virus (HIV) strains, simian immunodeficiency virus (SIV) gp130, and HIV type 1 (HIV-1) gp41 with affinity constants (KD) in the lower nM range. The gp120 and gp41 binding of AH is selectively reversed by (alpha1,2-mannose)3 oligosaccharide but not by alpha1,3/alpha1,6-mannose- or GlcNAc-based oligosaccharides. AH binding to gp120 prevents binding of alpha1,2-mannose-specific monoclonal antibody 2G12, and AH covers a broader epitope on gp120 than 2G12. Prolonged exposure of HIV-1-infected CEM T-cell cultures with escalating AH concentrations selects for mutant virus strains containing N-glycosylation site deletions (predominantly affecting high-mannose-type glycans) in gp120. In contrast to 2G12, AH has a high genetic barrier, since several concomitant N-glycosylation site deletions in gp120 are required to afford significant phenotypic drug resistance. AH is endowed with broadly neutralizing activity against laboratory-adapted HIV strains and a variety of X4 and/or R5 HIV-1 clinical clade isolates and blocks viral entry within a narrow concentration window of variation (approximately 5-fold). In contrast, the neutralizing activity of 2G12 varied up to 1,000-fold, depending on the virus strain. Since AH efficiently prevents syncytium formation in cocultures of persistently HIV-1-infected HuT-78 cells and uninfected CD4+ T lymphocytes, inhibits dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin-mediated capture of HIV-1 and subsequent virus transmission to CD4+ T lymphocytes, does not upregulate cellular activation markers, lacks mitogenic activity, and does not induce cytokines/chemokines in peripheral blood mononuclear cell cultures, it should be considered a potential candidate drug for microbicidal use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498311      PMCID: PMC2916299          DOI: 10.1128/AAC.00254-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping.

Authors:  F Yang; C A Bewley; J M Louis; K R Gustafson; M R Boyd; A M Gronenborn; G M Clore; A Wlodawer
Journal:  J Mol Biol       Date:  1999-05-07       Impact factor: 5.469

2.  Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete.

Authors:  Atsushi Takahashi; Junji Inokoshi; Harumi Chiba; Satoshi Omura; Haruo Tanaka
Journal:  Arch Biochem Biophys       Date:  2005-04-05       Impact factor: 4.013

3.  Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

Authors:  Dana Huskens; Kristel Van Laethem; Kurt Vermeire; Jan Balzarini; Dominique Schols
Journal:  Virology       Date:  2006-11-21       Impact factor: 3.616

Review 4.  Exploiting the defensive sugars of HIV-1 for drug and vaccine design.

Authors:  Christopher N Scanlan; John Offer; Nicole Zitzmann; Raymond A Dwek
Journal:  Nature       Date:  2007-04-26       Impact factor: 49.962

5.  Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.

Authors:  Jan Balzarini; Kristel Van Laethem; Willy J Peumans; Els J M Van Damme; Anders Bolmstedt; Federico Gago; Dominique Schols
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes.

Authors:  Jan Balzarini; Yven Van Herrewege; Kurt Vermeire; Guido Vanham; Dominique Schols
Journal:  Mol Pharmacol       Date:  2006-10-20       Impact factor: 4.436

7.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

8.  A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene.

Authors:  Kristel Van Laethem; Yoeri Schrooten; Philippe Lemey; Eric Van Wijngaerden; Stéphane De Wit; Marc Van Ranst; Anne-Mieke Vandamme
Journal:  J Virol Methods       Date:  2005-01       Impact factor: 2.014

9.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

10.  Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.

Authors:  Katrien Princen; Sigrid Hatse; Kurt Vermeire; Erik De Clercq; Dominique Schols
Journal:  Retrovirology       Date:  2004-03-08       Impact factor: 4.602

View more
  31 in total

1.  The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.

Authors:  Katrien O François; Jan Balzarini
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

Review 2.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

3.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

4.  Chemical and Biophysical Approaches for Complete Characterization of Lectin-Carbohydrate Interactions.

Authors:  Sabrina Lusvarghi; Rodolfo Ghirlando; Jack R Davison; Carole A Bewley
Journal:  Methods Enzymol       Date:  2017-07-23       Impact factor: 1.600

5.  The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.

Authors:  Jie Xue; Yongguang Gao; Bart Hoorelbeke; Ioannis Kagiampakis; Bo Zhao; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Mol Pharm       Date:  2012-08-21       Impact factor: 4.939

6.  Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains.

Authors:  Geoffrey Férir; Dana Huskens; Kenneth E Palmer; Daniel M Boudreaux; Michael D Swanson; David M Markovitz; Jan Balzarini; Dominique Schols
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

7.  A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets.

Authors:  Alex Stewart; Yanyun Liu; Jonathan R Lai
Journal:  J Immunol Methods       Date:  2011-12-31       Impact factor: 2.303

8.  Current progress and challenges in HIV gene therapy.

Authors:  Janet Chung; John J Rossi; Ulrike Jung
Journal:  Future Virol       Date:  2011-11-01       Impact factor: 1.831

9.  Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.

Authors:  Christopher Barton; J Calvin Kouokam; Amanda B Lasnik; Oded Foreman; Alexander Cambon; Guy Brock; David C Montefiori; Fakhrieh Vojdani; Alison A McCormick; Barry R O'Keefe; Kenneth E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

10.  Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family.

Authors:  Geoffrey Férir; Dana Huskens; Sam Noppen; Leonardus M I Koharudin; Angela M Gronenborn; Dominique Schols
Journal:  J Antimicrob Chemother       Date:  2014-06-25       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.